Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Lilly Endowment Inc. filed a Form 144 notice covering a proposed sale of 305,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets, with an aggregate market value of $323,208,500. The notice lists 945,383,757 Eli Lilly shares outstanding. The Endowment’s shares being sold trace back to a large historical gift; it reports acquiring 38,400,000 Eli Lilly common shares via a gift from the J.K. Lilly Sr. Trust dated in the 1930s–1940s.
The filing also details extensive recent selling activity by Lilly Endowment. Over the past three months, it executed multiple Eli Lilly stock sales on the NYSE and NASDAQ, including transactions such as 351,015 shares on 10/01/2025 for gross proceeds of $284,653,451.48 and 305,000 shares on 11/12/2025 for $308,411,211.50. Individual daily trades during this period often exceeded 100,000 shares, with gross proceeds frequently above $80 million per day.
Lilly Endowment Inc. filed a Form 144 notice covering a proposed sale of 305,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets, with an aggregate market value of $323,208,500. The notice lists 945,383,757 Eli Lilly shares outstanding. The Endowment’s shares being sold trace back to a large historical gift; it reports acquiring 38,400,000 Eli Lilly common shares via a gift from the J.K. Lilly Sr. Trust dated in the 1930s–1940s.
The filing also details extensive recent selling activity by Lilly Endowment. Over the past three months, it executed multiple Eli Lilly stock sales on the NYSE and NASDAQ, including transactions such as 351,015 shares on 10/01/2025 for gross proceeds of $284,653,451.48 and 305,000 shares on 11/12/2025 for $308,411,211.50. Individual daily trades during this period often exceeded 100,000 shares, with gross proceeds frequently above $80 million per day.
Eli Lilly and Company reported that its Board of Directors has elected Carolyn R. Bertozzi, Ph.D. as a new director, effective December 8, 2025. She is 59 and holds key academic roles at Stanford University, including Professor of Chemistry, Chemical & Systems Biology, and Radiology, and serves as an Investigator of the Howard Hughes Medical Institute.
Dr. Bertozzi will join Lilly’s Science and Technology Committee and the Ethics and Compliance Committee, bringing additional scientific and governance expertise. The Board has determined that she is independent under New York Stock Exchange standards and the company’s own guidelines. She will stand for election by shareholders at the annual meeting in May 2026 and will receive compensation under Lilly’s standard director compensation program.
Lilly Endowment Inc., a director of Eli Lilly & Co. (LLY), reported open-market sales of a total of 37,148 shares of common stock on 11/20/2025. The sales were executed in multiple tranches at weighted average prices ranging from $1,050.364 to $1,055.391 per share, with underlying trade prices spanning from $1,050.00 to $1,055.59, as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owns 92,607,304 shares of Eli Lilly common stock, held directly.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly and Company (LLY), reported multiple sales of Eli Lilly common stock on 11/19/2025. The transactions were open-market sales at weighted average prices between about $1,050 and $1,055 per share, executed in several blocks including 96,516 shares and 28,768 shares. After these sales, the reporting person beneficially owned 92,644,452 shares of Eli Lilly common stock, held directly. The prices disclosed are weighted averages for trades within narrow price ranges, and the reporting person notes that detailed trade information is available upon request.
Eli Lilly & Co. reported insider selling by a director on Form 4. On 11/18/2025, the reporting person executed a series of open-market sales of Eli Lilly common stock, coded "S" for sale. Across ten tranches, the director sold a total of 60,213 shares at weighted average prices ranging from about $1,030 to $1,040 per share, with each tranche reported alongside a specific weighted average price and price range.
Following these transactions, the reporting person directly beneficially owned 92,811,978 shares of Eli Lilly common stock. The filing notes that detailed breakouts of the individual trade prices within each weighted range are available upon request. The form is signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.
Lilly Endowment Inc. has filed a Form 144 indicating a planned sale of 310,000 shares of Eli Lilly and Company common stock through J.P. Morgan Securities LLC, with an aggregate market value of 319,315,500. The filing notes that Eli Lilly had 945,383,757 shares outstanding at the time of the notice and lists 11/19/2025 as the approximate sale date on the NYSE or NASDAQ.
The securities to be sold trace back to common stock originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust, in a transaction involving 38,400,000 shares. The notice also details a series of recent block sales of Eli Lilly common stock by Lilly Endowment Inc., including 351,015 shares sold on 10/01/2025 for 284,653,451.48 and 305,000 shares sold on 11/12/2025 for 308,411,211.50.
By signing, the seller represents that it is not aware of undisclosed material adverse information about Eli Lilly’s current or prospective operations.
Eli Lilly and Company director Kimberly H. Johnson reported buying 215.327 shares of Eli Lilly common stock on 11/17/2025. The Form 4 shows the shares were acquired at a price of $1,021.7 per share. After this transaction, she beneficially owns a total of 3,264.731 shares of Eli Lilly common stock directly.
Eli Lilly and Company director Gabrielle Sulzberger reported acquiring additional Eli Lilly (LLY) equity on Form 4. On 11/17/2025, she acquired 4.853 shares of common stock that, at her election, were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after she leaves the board. On the same date, she also acquired 215.327 shares of common stock. Following these transactions, she reported beneficial ownership of 2,948.32 shares of common stock in direct ownership form.
Eli Lilly and Company director reports stock purchase. A reporting person serving as a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025 at a price of $1,021.7 per share, according to a Form 4 filing. Following this transaction, the director beneficially owns 304.271 shares of Eli Lilly common stock in direct ownership.
Eli Lilly and Company director Juan R. Luciano reported acquiring a total of 229.845 shares of Lilly common stock on 11/17/2025. One transaction covered 14.518 shares that he elected to receive as stock units under the Lilly Directors' Deferral Plan instead of cash compensation, to be settled in shares after his separation from service. A second acquisition of 215.327 shares was also reported at a price of $1,021.7 per share. Following these transactions, Luciano directly beneficially owns 16,704.141 shares of Eli Lilly common stock.